Aerie Pharmaceuticals reported $311.68M in Debt for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Aerie Pharmaceuticals AERI:US $ 311.68M 77.15M
Alimera Sciences ALIM:US $ 43.6M 0.25M
Amarin AMRN:US $ 0M 0M
Bluebird Bio BLUE:US $ 0M 0M
Cara Therapeutics CARA:US $ 0 0
Coherus Biosciences CHRS:US $ 420.46M 10.94M
Endo International Ordinary Shares ENDP:US $ 8090.62M 183.92M
Horizon Pharma HZNP:US $ 2568.74M 2.49M
Insmed INSM:US $ 806.79M 225.49M
JAZZ PHA JAZZ:US $ 6023.87M 32.75M
Merk MRK:US $ 31794M 1308M
Mirati Therapeutics MRTX:US $ 0M 0M
Novartis NOVN:VX SF 31275M 250M
Ophthotech OPHT:US $ 0M 0M
Pacira Pharmaceuticals PCRX:US $ 923.42M 125.81M
Regeneron Pharmaceuticals REGN:US $ 2700.4M 0.7M
Revance Therapeutics RVNC:US $ 449.74M 169.1M
Supernus Pharmaceuticals SUPN:US $ 400.38M 21.13M
Teva Pharmaceutical Industries TEVA:US $ 22917M 126M
Valeant Pharmaceuticals VRX:CN $ 23168M 514M
Zoetis ZTS:US $ 6578M 14M